SCHEMBL3678849

SCHEMBL3678849

CC(=O)ON1C(=O)C(OC(=O)C2CCCCC2)C(OC(=O)C2CCCCC2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.41
CHRM4 P08173 2/20 0.41
CHRM1 P11229 2/20 0.41
CHRM3 P20309 2/20 0.41
SMN1; SMN2 Q16637 4/20 0.36
ALDH1A1 P00352 5/20 0.34
RBBP9 O75884 1/20 0.32
POLB P06746 4/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
CES2 O00748 1/20 0.31
CES1 P23141 1/20 0.31
TSHR P16473 2/20 0.31
RECQL P46063 1/20 0.31
LMNA P02545 1/20 0.31
NPC1 O15118 1/20 0.31
CASP3 P42574 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3681502 0.98 CHRM2 (0.39) CHRM2CHRM4CHRM1CHRM3SMN1; SMN2
SCHEMBL5080125 0.78 CHRM2 (0.43) CHRM2CHRM4CHRM1CHRM3SMN1; SMN2
SCHEMBL3681001 0.77 POLB (0.45) CHRM2CHRM4CHRM1CHRM3POLB
SCHEMBL5083681 0.76 CHRM2 (0.41) CHRM2CHRM4CHRM1CHRM3SMN1; SMN2
SCHEMBL1537360 0.74 HTT (0.39) SMN1; SMN2ALDH1A1POLBHTTKMT2A
SCHEMBL18840159 0.71 HTT (0.36) CHRM2CHRM4CHRM1CHRM3SMN1; SMN2
SCHEMBL18843394 0.71 HTT (0.36) CHRM2CHRM4CHRM1CHRM3SMN1; SMN2
SCHEMBL3682344 0.70 POLB (0.35) POLB
SCHEMBL3678626 0.70 POLB (0.35) POLBELANE
SCHEMBL3676892 0.70 ELANE (0.37) CHRM2CHRM4CHRM1CHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741514-B2 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2010-06-22 US disclosed
US-20060281629-A1 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst ISHII YASUTAKA 2006-12-14 US disclosed
US-7115541-B2 Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2006-10-03 US disclosed
EP-1338336-A1 CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS Daicel Chemical Industries, Ltd. (JP) 2003-08-27 EP disclosed
US-20030013603-A1 Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2003-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281629-A1 Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst NOS2, NOS1, NOS3 CHRM2 268/4885CHRM4 869/4885CHRM1 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.